Brain Circul: Scientists have developed a new strategy for treating stroke

JANUARY 4, 2021 // -- In a recent study published in the international journal Brain Transaction, scientists from Louisiana State University and other institutions said they developed a patented drug and a selective DHA derivative that may be effective in protecting brain cells and increasing post-stroke symptom recovery compared to a single drug.
researcher Nicolas Bazan says that using experimental models may help develop new therapeutic strategies for treating isothermic strokes, where special signals are produced by primary brain immune cells that reach white blood cells and are called small glial cells, which can cause neuroinflamm, leading to the accumulation of chemicals that damage the brain, and the accumulation of plate plate activators (PAFs), which play a key role in neuron survival.
in an earlier study, the researchers found that, in addition to the anti-inflammatory properties, DHA, a necessary Ω-3 fatty acid, stimulates the production of NPD1 (Neuroprotectin D1), a special molecule that protects brain cells and promotes their survival, and that a complex factor in developing neuropulation strategies for treating strokes is the multiple path paths and events that occur in the brain during stroke, which are largely unsuccessful, but mostly not successful.
Photo Source: Louisiana State University has not been shown to be effective in treating complex strokes, so researchers have targeted two different events that block the inflammatory plate platea-activator-activator complex (PAF-R) and activate cell survival path path paths.
researchers found that using a molecule synthesized in the lab, LAU-0901, which blocks inflammatory plate platea activators, NPD1 (AT-NPD1) triggered by aspirin may reduce the size of damaged areas of the brain and initiate repair mechanisms that can significantly improve recovery of body behavior.
researchers said that LAU-0901 combined NPD1 can reduce the total lesion volume by 62%, LAU-0901 combined AT-NPD1 may reduce the overall lesion volume by 90%.
LAU-0901 combined AT-NPD1 combination therapy was able to improve the body's behavior score to 54% on the third day, and LAU-0901 and LAU-0901 plus DHA were able to reduce the production of inflammatory mediators called 12-hydroxy-20 carbon dioxide.
Dr. Bazan said the biological activity of LAU-0901 in combination with AT-NPD1 is determined by the activation or regulation of signaling pathways that interact with immune cells, inflammation, cell survival, and cell-to-cell interactions, and studies have found that they are critical to the development of new therapies for a variety of human diseases, including stroke and neurodegenerative diseases.
these new molecules can promote the survival of nerve cells with significant anti-inflammatory activity, and these combination therapies may hopefully help treat isothermal stroke in the future, the researchers said.
about one person in the U.S. has a stroke every 40 seconds, and one person dies every four minutes, according to the CDC.
more than 795,000 people in the U.S. suffer from stroke each year, and about 87 percent of strokes are is istemia strokes, in which blood flow in the brain is blocked.
2014-2015, stroke-related costs in the United States were close to $46 billion, including health care for patients, the cost of medications to treat strokes, and the cost of absence.
stroke is the leading cause of long-term severe disability in the population, with more than half of stroke survivors over the age of 65 suffering from reduced mobility as a result of a stroke.
() Original source: Ludmila Belayev, Andre Obenaus, Pranab K Mukherjee, et al. Blocking pro-inflammatory platelet-activating factor receptors and activating cell survival pathways: A novel therapeutic strategy in experimental ischemic stroke,Brain Circ 2020; 6:260-8, doi:10.4103/bc.bc_36_20